PIMS-TS patients exhibited higher systemic markers of inflammation when compared to acute COVID-19 patients, including leucocytosis (p = 0.01), neutrophilia and elevated CRP (p < 0.001) (Table 4). This evidence concerns the gene CRP and COVID-19.